What is the typical dose of Trelegy (fluticasone furoate, umeclidinium, and vilanterol)?

From the Guidelines

The typical dose of Trelegy is one inhalation once daily, containing 100/62.5/25 mcg or 200/62.5/25 mcg of fluticasone furoate, umeclidinium, and vilanterol, respectively. The medication is a combination of three active ingredients: fluticasone furoate (an inhaled corticosteroid), umeclidinium (a long-acting muscarinic antagonist), and vilanterol (a long-acting beta2-agonist) 1. Key points to consider when prescribing Trelegy include:

• The strength of the medication, which is determined by the healthcare provider based on the condition severity
• The proper use of the Ellipta inhaler device, which requires the patient to open the cover until a click is heard, then inhale the medication deeply through the mouth
• The importance of rinsing the mouth after use to prevent thrush
• The need to not stop taking the medication without consulting a doctor It is essential to note that Trelegy should not be used for acute bronchospasm or asthma attacks requiring immediate relief, as it is designed for long-term control and prevention of symptoms 1. The medication works by reducing inflammation in the airways, relaxing airway muscles, and keeping airways open for a full 24 hours, making it effective for conditions like COPD or certain cases of asthma. In terms of dosing, the study provides information on the withdrawal schedule for various medications, including long-acting muscarinic acetylcholine antagonists and ultra-LABAs, but it does not directly address the typical dose of Trelegy 1. However, based on the available evidence, the recommended dose of Trelegy is one inhalation once daily, with the specific strength determined by the healthcare provider.

From the Research

Typical Dose of Trelegy

• The typical dose of Trelegy (fluticasone furoate, umeclidinium, and vilanterol) is not explicitly stated in the provided studies, but the composition of Trelegy Ellipta is mentioned as containing fluticasone furoate, vilanterol trifenatate, and umeclidinium bromide 2.
• The doses of the individual components in Trelegy are mentioned in other studies:
  • Fluticasone furoate at a dose of 100 μg and vilanterol at a dose of 25 μg 3.
  • Umeclidinium at doses of 62.5 μg and 125 μg, with fluticasone furoate/vilanterol at 100/25 μg 4.
  • The specific combination of fluticasone furoate/umeclidinium/vilanterol 100/62.5/25 µg is mentioned in a study evaluating the effectiveness of this triple therapy in patients with COPD 5.

Key Findings

• The effectiveness and safety of Trelegy and its components have been evaluated in several studies, demonstrating improvements in lung function and health status in patients with COPD 4, 3, 5, 6.
• These studies provide evidence for the use of triple therapy in COPD, including the combination of fluticasone furoate, umeclidinium, and vilanterol, but do not explicitly state the typical dose of Trelegy.